719870
Resomer® RG 503 H，聚(D,L-丙交酯-共-乙交酯)
acid terminated, lactide:glycolide 50:50, Mw 24,000-38,000
别名:
聚（D,L-丙交酯-co-乙交酯）, RESOMER® RG 503 H, PLGA
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Quality Level
form
amorphous
feed ratio
lactide:glycolide 50:50
mol wt
Mw 24,000-38,000
degradation timeframe
<3 months
viscosity
0.32-0.44 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer)
transition temp
Tg 44-48 °C
storage temp.
2-8°C
SMILES string
OCC(O)=O.CC(O)C(O)=O
InChI key
XBBVURRQGJPTHH-UHFFFAOYSA-N
Application
控释
Features and Benefits
控释生物活性剂、缝线和可生物吸收植入器件。
Physical form
具有生物相容性且可生物降解的聚合物。
Legal Information
Evonik产品
RESOMER is a registered trademark of Evonik Rohm GmbH
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
商品
In the past two decades, tissue engineering and regenerative medicine have become important interdisciplinary fields that span biology, chemistry, engineering, and medicine.
Innovations in polymer technology have had a significant impact on the advancement of novel drug delivery systems.
AliAliphatic polyesters, including polylactide and polyglycolide, are biodegradable polymers widely used in medical applications.
Kaamini M Dhanabalan et al.
Biomaterials science, 8(15), 4308-4321 (2020-07-01)
Osteoarthritis (OA) is a joint disease characterized by progressive damage of articular cartilage and the adjoining subchondral bone. Chondrocytes, the primary cells of the cartilage, have limited regenerative capacity and when they undergo stress due to trauma or with aging
Teresa Musumeci et al.
International journal of pharmaceutics, 440(2), 135-140 (2012-10-20)
Melatonin, a neurohormone secreted by the pineal gland, is able to modulate intraocular pressure (IOP). The aim of this study was to generate nanoparticle (NPs) sustained release formulations that allow to extend the pre-corneal residence time of melatonin, thus prolonging
Maria Kirzhner et al.
Ophthalmology, 120(6), 1300-1304 (2013-02-13)
To compare wrapped and polymer-coated hydroxyapatite implants in children undergoing primary enucleation with no adjuvant therapies. Retrospective, interventional cohort study. All children undergoing primary enucleation without adjuvant therapies between 1999 and 2009 at a tertiary pediatric cancer hospital. Review and
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 719870-5G | 04061835563692 |
| 719870-1G | 04061832855417 |